CTLA4 and hepatocellular carcinoma: The results showed that patients in the low-risk group exhibited higher IPS, involving four IPS subtypes [IPS-CTLA4(−)/PD-1(+), IPS-CTLA4(−)/PD-1(+), IPS-CTLA4(+)/PD-1(−), and IPS-CTLA4(+)/PD-1(+)], suggesting that HCC patients with low risk might benefit more from ICI therapy (Figures 10F–I).